Wallace D J, Linker-Israeli M, Metzger A L, Stecher V J
Cedars-Sinai Medical Center, Los Angeles.
Lupus. 1993 Feb;2 Suppl 1:S13-5.
Hydroxychloroquine has several less well-known actions that may have clinical relevance in treating systemic lupus erythematosus (SLE). (1) Hydroxychloroquine has a possible anti-thrombotic action. It is a platelet inhibitor and appears to decrease the risk of thromboembolism in patients with anticardiolipin antibodies. (2) Hydroxychloroquine is associated with lower serum cholesterol and low-density lipoprotein levels compared to those present in patients who are taking corticosteroids but not antimalarials for SLE. (3) It may also decrease abnormal levels of cytokines. Interleukin-6 (IL-6), soluble CD8 and soluble IL-2 receptors (sIL-2R) are lower in patients taking antimalarials compared to those on corticosteroids alone or on neither medication. Serum levels of CD8 and sIL-2R decrease after 6 weeks of hydroxychloroquine treatment. These findings may help explain the favorable response of SLE patients treated with antimalarials.
羟氯喹具有几种不太为人所知的作用，这些作用可能在治疗系统性红斑狼疮（SLE）方面具有临床意义。（1）羟氯喹可能具有抗血栓形成作用。它是一种血小板抑制剂，似乎能降低抗心磷脂抗体患者发生血栓栓塞的风险。（2）与使用皮质类固醇而非抗疟药治疗SLE的患者相比，羟氯喹与较低的血清胆固醇和低密度脂蛋白水平相关。（3）它还可能降低细胞因子的异常水平。与单独使用皮质类固醇或未使用任何药物的患者相比，服用抗疟药的患者白细胞介素-6（IL-6）、可溶性CD8和可溶性IL-2受体（sIL-2R）水平较低。羟氯喹治疗6周后，血清CD8和sIL-2R水平下降。这些发现可能有助于解释接受抗疟药治疗的SLE患者的良好反应。
